
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is a promising biotechnology company with a strong platform technology and a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's focus on DR3 antagonism has shown promising results in clinical trials, with strong receptor occupancy and no observed DR3 agonism. The development of a half-life extended version of their lead asset and other preclinical bispecific antibodies speaks to the potential of their platform technology. The risks for their success lie in clinical and regulatory outcomes, as well as potential competition from other companies in the highly competitive space of TL1A/DR3 targeting.
Bears say
Shattuck Labs is facing several challenges, including a lack of current revenue and upcoming catalysts for their main program SL-325, which may not be enough to sustain the company in the long term. Additionally, competition in the TL1A space, potential immunogenicity issues, and doubts about the potential success of their TL1A candidates in IBD may lower investor confidence and hinder the company's growth. As a result, the negative outlook on this stock is justified.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares